**Conflict of interest**

No conflicts of interests.

*The Recent Topics in Genetic Polymorphisms*

**References**

s0065-2660(01)42016-5

DOI: 10.1038/gene.2012.46

Roifman CM. Cloning and

2013-2024

ng1673

**103**

2009;**182**:3343-3347

[1] Weber JL, Broman KW. Genotyping for human whole-genome scans: Past, present, and future. Advances in Genetics. 2001;**42**:77-96. DOI: 10.1016/

*DOI: http://dx.doi.org/10.5772/intechopen.90836*

diseases. Seminars in Immunology.

Srivastava V, Tiwari R, Sharma RD. Understanding autoimmune disease: An update review. International Journal of Pharmaceutical Technology and Biotechnology. 2016;**3**(3):51-65

[10] Ortonne JP. Recent developments in the understanding of pathogenesis of psoriasis. The British Journal of Dermatology. 1999;**140**(Suppl 54):1-7

[12] Gregersen PK. Genetic analysis of rheumatic diseases. In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CN, editors. Textbook of Rheumatology. 5th ed. Vol. 1. Philadelphia: W.B. Saunders;

[13] Encinas JA, Kuchroo VK. Mapping and identification of autoimmunity genes. Current Opinion in Immunology.

[14] Becker KG. Comparative genetics of type I diabetes and autoimmune disease: Common loci, common pathways? Diabetes. 1999;**48**:1353-1358

[15] Sehgal VN, Srivastava G. Vitiligo: Compendium of clinico-epidemiological features. Indian Journal of Dermatology, Venereology and Leprology. 2007;**73**(3):

[16] Guerra L, Dellambra E, Brescia S, Raskovic D. Vitiligo: pathogenetic hypotheses and targets for current therapies. Current Drug Metabolism.

[17] Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo

[9] Singh SP, Wal P, Wal A,

[11] Kukreja A, Maclaren NK. Autoimmunity and diabetes. The Journal of Clinical Endocrinology and Metabolism. 1999;**84**:4371-4378

1997. pp. 209-211

2000;**12**:691-697

149-156

2010;**11**(5):451-467

2006;**18**:207-213

*The Protein Tyrosine Phosphatase Non-Receptor Type 22 (PTPN22) Gene Polymorphism…*

[2] Zheng J, Ibrahim S, Petersen F, Yu X. Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the

localization of the affected tissue. Genes and Immunity. 2012;**13**(8):641-652.

[3] Tizaoui K, Kim SH, Jeong GH, et al. Association of PTPN22 1858C/T polymorphism with autoimmune diseases: A systematic review and Bayesian approach. Journal of Clinical Medicine. 2019;**8**(3):347. Published 12 March 2019. DOI: 10.3390/jcm8030347

[4] Cohen S, Dadi H, Shaoul E, Sharfe N,

characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp. Blood. 1999;**93**:

[5] Vang T, Congia M, Macis MD, et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-offunction variant. Nature Genetics. 2005;**37**(12):1317-1319. DOI: 10.1038/

[6] Arechiga AF, Habib T, He Y, et al. Cutting edge: The PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. Journal of Immunology.

[7] Bottini N, Musumeci L, Alonso A, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nature Genetics. 2004; **36**(4):337-338. DOI: 10.1038/ng1323

[8] Bottini N, Vang T, Cucca F, Mustelin T. Role of PTPN22 in type 1 diabetes and other autoimmune
